Compare EKSO & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EKSO | DARE |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 27.9M |
| IPO Year | N/A | N/A |
| Metric | EKSO | DARE |
|---|---|---|
| Price | $7.12 | $1.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $9.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 5.9M | 104.1K |
| Earning Date | 03-02-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,749,000.00 | N/A |
| Revenue This Year | N/A | $3,843.33 |
| Revenue Next Year | $54.65 | $8,700.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.73 | $1.61 |
| 52 Week High | $12.70 | $9.19 |
| Indicator | EKSO | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 45.71 |
| Support Level | $7.70 | $1.88 |
| Resistance Level | $9.11 | $2.07 |
| Average True Range (ATR) | 1.09 | 0.10 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 3.80 | 25.10 |
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.